hydroxyurea has been researched along with Diseases, Peripheral Vascular in 1 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hydroxyurea has proven safety, feasibility, and efficacy in children with sickle cell anemia in sub-Saharan Africa, with studies showing a reduced incidence of vaso-occlusive events and reduced mortality." | 2.94 | Hydroxyurea Dose Escalation for Sickle Cell Anemia in Sub-Saharan Africa. ( Hume, HA; John, CC; Kasirye, P; Lane, A; Latham, TS; Nabaggala, C; Ndugwa, CM; Opoka, RO; Ware, RE, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| John, CC | 1 |
| Opoka, RO | 1 |
| Latham, TS | 1 |
| Hume, HA | 1 |
| Nabaggala, C | 1 |
| Kasirye, P | 1 |
| Ndugwa, CM | 1 |
| Lane, A | 1 |
| Ware, RE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Optimizing Hydroxyurea Therapy in Children With Sickle Cell Anemia In Malaria Endemic Areas: The NOHARM Maximum Tolerated Dose (MTD) Study[NCT03128515] | Phase 3 | 187 participants (Actual) | Interventional | 2017-07-26 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for hydroxyurea and Diseases, Peripheral Vascular
| Article | Year |
|---|---|
Hydroxyurea Dose Escalation for Sickle Cell Anemia in Sub-Saharan Africa.
Topics: Anemia, Sickle Cell; Antisickling Agents; Child, Preschool; Dose-Response Relationship, Drug; Double | 2020 |